Ajay Mehta - Concepedia

Author

Ajay Mehta

HCG NCHRI Cancer Centre

Also Known As

AJAY MEHTA, Ajay Mehta, Ajay O. Mehta, Ajay Omprakash Mehta, Alexandra McCarrick, Bryce, Richard

Publications

1.2K

Citations

H-Index

Concepts

All Affiliations

HCG NCHRI Cancer Centre Tata Memorial Hospital Ruby Hall Clinic Advaxis (United States)Christian Medical College, Vellore

About

Ajay Mehta is an author at HCG NCHRI Cancer Centre specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	123
2	Public Health	2	2	53
3	Business	1	1	36
4	Engineering	1	1	17
5	Management	1	1	36

Ajay Mehta

Publications

689

Citations

H-Index

Page 1

	Year	Citations
Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer Ahmad Awada, Rámón Colomer, Kenichi Inoue, JAMA Oncology	2016	310
A Randomized Phase 2 Study of ADXS11-001 Listeria monocy'togenes-Listeriolysin O Immunotherapy With or Without Cisplatin in Treatment of Advanced Cervical Cancer Partha Basu, Ajay Mehta, Minish Jain, International Journal of Gynecological Cancer	2018	171
The Moderating and Mediating Role of Corporate Reputation in the Link Between Service Innovation and Cross-Buying Intention Ajay Mehta Corporate Reputation Review Customer SatisfactionMediating RoleService InnovationCorporate ReputationManagement	2018	36
ADXS11-001 immunotherapy targeting HPV-E7: Final results from a phase 2 study in Indian women with recurrent cervical cancer. Partha Basu, Ajay Mehta, Minish Jain, Journal of Clinical Oncology ImmunodeficienciesImmunologyImmunoeditingImmunotherapeuticsImmunotherapy	2014	32
Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D) Alvaro Moreno‐Aspitia, Eileen Holmes, Christian Jackisch, European Journal of Cancer Clinical TrialsRandomized Controlled TrialDrug TrialMedicineBig 2-06/Alliance	2021	28
ADXS11-001 immunotherapy targeting HPV-E7: final results from a Phase II study in Indian women with recurrent cervical cancer Robert G. Petit, Ajay Mehta, Minish Jain, Journal for ImmunoTherapy of Cancer Microbial PathogensImmunologyImmunodominanceAntigen ProcessingImmunotherapeutics	2014	21
Nutritional status and symptom burden in advanced non-small cell lung cancer: results of the dietetic assessment and intervention in lung cancer (DAIL) trial I. Phillips, Lindsey Allan, Adele Hug, BMJ Supportive & Palliative Care	2021	19
Further Improvement on GPU-Based Parallel Implementation of WRF 5-Layer Thermal Diffusion Scheme Melin Huang, Bormin Huang, Jarno Mielikäinen, 2013 International Conference on Parallel and Distributed Systems EngineeringGpu ComputingGround Heat FluxHeat Transfer ProcessNumerical Weather Prediction	2013	17
LUX-breast 1: Randomized, phase III trial of afatinib and vinorelbine versus trastuzumab and vinorelbine in patients with HER2-overexpressing metastatic breast cancer (MBC) failing one prior trastuzumab treatment. Nadia Harbeck, Seock‐Ah Im, Chiun‐Sheng Huang, Journal of Clinical Oncology Breast OncologyTps649 BackgroundMedicinePharmacologyClinical Trials	2012	16
LUX-breast 2: Phase II, open-label study of oral afatinib in HER2-overexpressing metastatic breast cancer (MBC) patients (pts) who progressed on prior trastuzumab (T) and/or lapatanib (L). Tamas Hickish, Ling‐Ming Tseng, Ajay Mehta, Journal of Clinical Oncology Breast OncologyPathologyPharmacotherapyTumor BiologyTps651 Background	2012	13

Page 1